77 related articles for article (PubMed ID: 10380754)
1. Cleavage of double-stranded copy RNA by RNase 1 and RNase T1 provides a robust means to detect p53 gene mutations in clinical specimens.
Prescott J; Patel H; Tillman S; McHugh T; Ralph D
Electrophoresis; 1999 Jun; 20(6):1149-61. PubMed ID: 10380754
[TBL] [Abstract][Full Text] [Related]
2. NIRCA: a rapid robust method for screening for unknown point mutations.
Goldrick MM; Kimball GR; Liu Q; Martin LA; Sommer SS; Tseng JY
Biotechniques; 1996 Jul; 21(1):106-12. PubMed ID: 8816244
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma.
Salinas-Sánchez AS; Atienzar-Tobarra M; Lorenzo-Romero JG; Sánchez-Sánchez F; Giménez-Bachs JM; Donate-Moreno MJ; Pastor-Navarro H; Hernández-Millán I; Segura-Martín M; Escribano-Martínez J
Urol Int; 2007; 79(4):321-7. PubMed ID: 18025850
[TBL] [Abstract][Full Text] [Related]
4. Selective detection of inactivating mutations of the tumor suppressor gene p53 in bladder tumors.
Pfister C; Flaman JM; Martin C; Grise P; Frebourg T
J Urol; 1999 Jun; 161(6):1973-5. PubMed ID: 10332483
[TBL] [Abstract][Full Text] [Related]
5. RNase cleavage-based methods for mutation/SNP detection, past and present.
Goldrick MM
Hum Mutat; 2001 Sep; 18(3):190-204. PubMed ID: 11524730
[TBL] [Abstract][Full Text] [Related]
6. p53 mutations as a marker of malignancy in bladder washing samples from patients with bladder cancer.
Phillips HA; Howard GC; Miller WR
Br J Cancer; 2000 Jan; 82(1):136-41. PubMed ID: 10638980
[TBL] [Abstract][Full Text] [Related]
7. Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.
Ecke TH; Lenk SV; Schlechte HH; Loening SA
Anticancer Res; 2003; 23(2A):957-62. PubMed ID: 12820330
[TBL] [Abstract][Full Text] [Related]
8. Screen p53 mutations in hepatocellular carcinoma by FASAY: a novel splicing mutation.
Wu XM; Fu JG; Ge WZ; Zhu JY; Wang JY; Zhang W; Qian W; Huo KK
J Zhejiang Univ Sci B; 2007 Feb; 8(2):81-7. PubMed ID: 17266182
[TBL] [Abstract][Full Text] [Related]
9. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
[TBL] [Abstract][Full Text] [Related]
10. Alport syndrome. Molecular genetic aspects.
Hertz JM
Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
[TBL] [Abstract][Full Text] [Related]
11. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer.
George B; Datar RH; Wu L; Cai J; Patten N; Beil SJ; Groshen S; Stein J; Skinner D; Jones PA; Cote RJ
J Clin Oncol; 2007 Dec; 25(34):5352-8. PubMed ID: 18048815
[TBL] [Abstract][Full Text] [Related]
12. Quantitative detection of mutant alleles of the K-ras gene with minor groove binder-conjugated fluorogenic DNA probes.
Itabashi T; Maesawa C; Uchiyama M; Higuchi T; Masuda T
Int J Oncol; 2004 Mar; 24(3):687-96. PubMed ID: 14767554
[TBL] [Abstract][Full Text] [Related]
13. Detection of clinically relevant point mutations by a novel piezoelectric biosensor.
Dell'Atti D; Tombelli S; Minunni M; Mascini M
Biosens Bioelectron; 2006 Apr; 21(10):1876-9. PubMed ID: 16388945
[TBL] [Abstract][Full Text] [Related]
14. Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study.
Fouquet C; Antoine M; Tisserand P; Favis R; Wislez M; Commo F; Rabbe N; Carette MF; Milleron B; Barany F; Cadranel J; Zalcman G; Soussi T
Clin Cancer Res; 2004 May; 10(10):3479-89. PubMed ID: 15161705
[TBL] [Abstract][Full Text] [Related]
15. Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response.
Deissler H; Kafka A; Schuster E; Sauer G; Kreienberg R; Zeillinger R
Oncol Rep; 2004 Jun; 11(6):1281-6. PubMed ID: 15138567
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.
Powell B; Soong R; Iacopetta B; Seshadri R; Smith DR
Clin Cancer Res; 2000 Feb; 6(2):443-51. PubMed ID: 10690522
[TBL] [Abstract][Full Text] [Related]
17. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
[TBL] [Abstract][Full Text] [Related]
18. Sensitive detection of p53 mutation: analysis by direct sequencing and multisequence analysis.
Rozemuller EH; Kropveld A; Kreyveld E; Leppers FG; Scheidel KC; Slootweg PJ; Tilanus MG
Cancer Detect Prev; 2001; 25(2):109-16. PubMed ID: 11341345
[TBL] [Abstract][Full Text] [Related]
19. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients.
Liu D; Huang CL; Kameyama K; Hayashi E; Yamauchi A; Sumitomo S; Yokomise H
Cancer; 2002 Apr; 94(8):2239-47. PubMed ID: 12001123
[TBL] [Abstract][Full Text] [Related]
20. A rapid fluorescence based multiplex polymerase chain reaction--single-strand conformation polymorphism method for p53 mutation detection.
Berggren P; Steineck G; Hemminki K
Electrophoresis; 2000 Jul; 21(12):2335-42. PubMed ID: 10939443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
